DexCom, Inc. (DXCM)
$
85.33
+0.82 (0.96%)
Key metrics
Financial statements
Free cash flow per share
1.4707
Market cap
33.1 Billion
Price to sales ratio
7.9887
Debt to equity
1.1397
Current ratio
1.4994
Income quality
1.8014
Average inventory
540.4 Million
ROE
0.2438
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
DexCom, Inc. is a medical device company that specializes in the design, development, and commercialization of continuous glucose monitoring (CGM) systems globally. The company earned an interest income of $134,200,000.00 showcasing its financial investments. Its products are utilized by individuals with diabetes and healthcare providers alike, featuring systems such as the DexCom G6, an integrated CGM system for effective diabetes management. The earnings before interest, taxes, depreciation, and amortization (EBITDA) is $945,700,000.00 a key indicator of the company's operational profitability. The company's product range also includes the Dexcom Real-Time API, which allows third-party developers to integrate real-time CGM data into digital health applications, and the Dexcom ONE, designed to eliminate the need for finger-stick blood glucose testing for diabetes treatment decisions. Additionally, DexCom Share provides remote monitoring capabilities. The company recorded an operating income of $600,000,000.00 reflecting its earnings from core operations, and the earnings per share (EPS) is reported at $1.46 indicating the company's profitability on a per-share basis. With a weighted average number of shares outstanding of 404,624,602.00 the company's shareholder base is highlighted, demonstrating its broad market engagement. The candidate for new offerings includes the next-generation Dexcom G7 CGM system, which is anticipated to enhance its product lineup. Furthermore, DexCom, Inc. has established a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop innovative blood-based or interstitial glucose monitoring products, marking an exciting expansion for the firm. In terms of market positioning, the stock is reasonably priced at $85.33 appealing to a broad range of investors. The stock exhibits a high average trading volume of 4,429,610.00 indicating strong liquidity in the market. With a mid-range market capitalization of $33,458,490,310.00 the company is a steady performer within its sector. It is a key player in the Medical - Devices industry, contributing significantly to the overall market landscape. Additionally, DexCom, Inc. belongs to the Healthcare sector, driving innovation and growth, which positions the company favorably for future advancements and investor interest.
What is DexCom, Inc. (DXCM)'s stock forecast?
Analysts predict DexCom, Inc. stock to fluctuate between $57.52 (low) and $128.63 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is DexCom, Inc.'s market capitalization?
As of 2025-05-27, DexCom, Inc.'s market cap is $33,458,490,310, based on 392,107,000 outstanding shares.
How does DexCom, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., DexCom, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy DexCom, Inc. (DXCM) stock?
To buy DexCom, Inc. (DXCM) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for DXCM. Place an order (Market, Limit, etc.).
What is the best time to invest in DexCom, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has DexCom, Inc. stock ever split?
DexCom, Inc.'s last stock split was 4:1 on 2022-06-13.
How did DexCom, Inc. perform in the last earnings report?
Revenue: $4,033,000,000 | EPS: $1.46 | Growth: 1.39%.
Where can I find DexCom, Inc.'s investor relations reports?
Visit https://www.dexcom.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for DexCom, Inc.?
You can explore historical data from here
What is the all-time high and low for DexCom, Inc. stock?
All-time high: $164.86 (2021-11-18) | All-time low: $57.52 (2025-04-04).
What are the key trends affecting DexCom, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
fool.com
Investors typically want to beat the market over the long run. Though it's not an easy task, it certainly is possible with the right companies.
marketbeat.com
DexCom, Inc. NASDAQ: DXCM has once again demonstrated its formidable position in the continuous glucose monitoring (CGM) market, delivering outstanding first-quarter 2025 financial results that underscore its sustained momentum. The company's performance, driven by strong product demand, successful innovation, and strategic market access expansion, strongly supports an ambitious trajectory for the remainder of 2025, indicating a clear path towards further solidifying its leadership in diabetes technology.
zacks.com
The S&P 500 is enjoying its longest winning streak since 2004. We have highlighted the five best stocks in the S&P 500 over the past month.
seekingalpha.com
I initially rated DexCom's stock as sell due to competition and GLP-1 threats, but surprising 1Q25 growth prompts an upgrade to hold. DXCM posted better than expected growth figures in 1Q25, establishing a reaccelerating trend in growth for the company. However, DXCM's competitor product, Abbott's Libre Freestyle, has been growing faster despite larger sales.
zacks.com
DXCM's first-quarter 2025 earnings decline despite increasing sales. Its performance in 2025 is expected to be fueled by global growth in CGM adoption, strong Sensor sales and expansion into new markets.
fool.com
Marketwide challenges, like those created by President Donald Trump's tariff policies, cause many investors to shift their focus to the short term -- leading to panic-selling and a spiraling stock market. While it's a perfectly human reaction to volatility, it's a tendency investors should avoid.
seekingalpha.com
DexCom, Inc. (NASDAQ:DXCM ) Q1 2025 Earnings Conference Call May 1, 2025 4:30 PM ET Company Participants Sean Christensen - VP, Finance & IR Kevin Sayer - Executive Chairman, CEO & President Jereme Sylvain - EVP, CFO & Chief Accounting Officer Jacob Leach - EVP & COO Conference Call Participants Matt Taylor - Jefferies Robbie Marcus - JPMorgan Danielle Antalffy - UBS Jeff Johnson - Baird Jayson Bedford - Raymond James Travis Steed - Bank of America Merrill Lynch Matt O'Brien - Piper Sandler Marie Thibault - BTIG Joanne Wuensch - Citibank Michael Polark - Wolfe Research Margaret Andrew - William Blair Mike Kratky - Leerink Partners Colin Clark - Stifel, Nicolaus & Company Issie Kirby - Redburn Bill Plovanic - Canaccord Chris Pasquale - Nephron Steve Lichtman - Oppenheimer & Co. Matt Miksic - Barclays Anthony Petrone - Mizuho Group Operator Welcome to the DexCom First Quarter 2025 Earnings Release Conference Call. My name is Louella, and I will be your operator for today's call.
globenewswire.com
SAN DIEGO, April 22, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP, a leading stockholder rights law firm, has initiated an investigation into the board members and executive officers of DexCom, Inc. (NASDAQ: DXCM) for potential breaches of fiduciary duties and violations of the federal securities laws.
prnewswire.com
NEW YORK , April 22, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of DexCom, Inc. (NASDAQ: DXCM) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, DexCom insiders caused the company to misrepresent or fail to disclose material information concerning expected revenue for the fiscal year 2024.
businesswire.com
SAN DIEGO--(BUSINESS WIRE)--Johnson Fistel, PLLP, a leading stockholder rights law firm, has initiated an investigation into the board members and executive officers of DexCom, Inc. (NASDAQ: DXCM) for potential breaches of fiduciary duties and violations of the federal securities laws. What is Johnson Fistel Investigating? Between April 28, 2023 and June 5, 2024, certain DexCom insiders caused the company to issue false and misleading public statements regarding its expansion strategy and purpo.
See all news
